SGX301
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SGX301, covering 2022-04-15 to 2022-04-15. Get the full timeline:
Most recent: Clinical Trial Update: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Phase 3]